mitoxantrone has been researched along with Germinoblastoma in 83 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol." | 9.22 | Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. ( Lee, JJ; Liao, AT; Wang, SL, 2016) |
| " In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)." | 9.11 | Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005) |
| "Fifty-one patients with recurrent or refractory indolent lymphoma were treated with a regimen of fludarabine 25 mg/m2/d intravenously (IV) on days 1 to 3, mitoxantrone 10 mg/m2 IV on day 1, and dexamethasone 20 mg/d IV or orally on days 1 to 5." | 9.08 | Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. ( Cabanillas, F; Hagemeister, FB; Keating, M; McLaughlin, P; Pate, O; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1996) |
| "We have previously reported that combination chemotherapy based on the drugs cytarabine/platinum is effective in recurring lymphomas." | 9.08 | A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. ( Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W, 1995) |
| "We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)." | 9.07 | Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994) |
| "We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs." | 9.07 | [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993) |
| "We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation." | 9.07 | Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ( Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993) |
| "Oral VP-16 combined with ifosfamide/mesna and mitoxantrone at the doses and schedules indicated has little activity against relapsed and/or refractory lymphomas." | 9.07 | A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. ( Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1994) |
| " A phase II study was performed at the MTD of paclitaxel in patients with doxorubicin/mitoxantrone-refractory metastatic breast cancer." | 9.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "Mitoxantrone was administered to 74 dogs with lymphoma at a dosage of 5." | 9.07 | Evaluation of mitoxantrone for the treatment of lymphoma in dogs. ( Cotter, SM; Dennis, RA; Getzy, DM; L'Heureux, DA; Moore, AS; Ogilvie, GK; Rand, WS; Ruslander, D, 1994) |
| "As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease." | 9.07 | Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. ( Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ, 1991) |
| "In order to compare the efficacy and toxicity of mitoxantrone and adriamycin in non-Hodgkin's lymphoma, a randomized trial has been conducted by a cooperative study group since June 1984." | 9.06 | [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. ( Kimura, I; Masaoka, T; Namba, K; Ohnoshi, T; Sampi, K, 1986) |
| "Twenty-seven patients with failed malignant lymphomas (19 with intermediate grade, 4 with low-grade, 3 with high-grade lymphomas, and 1 with Hodgkin's disease) who had failed a median of 3 prior multidrug regimens, all previously exposed to anthracyclines (median prior doxorubicin 360 mg/m2), were treated with a combination of mitoxantrone (M), vincristine (V), and dexamethasone (D) every 4 weeks." | 9.06 | Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphoma. ( Crown, JC; Holland, JF; Paciucci, PA, 1989) |
| " The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma." | 7.73 | Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. ( Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A, 2005) |
| "Hematological and extrahematological toxicity of high-dose (hd) mitoxantrone (MITO) and melphalan (L-PAM) as conditioning regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at disease onset)." | 7.71 | High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. ( Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Gianni, AM; Ladetto, M; Pileri, A; Podio, V; Rossi, G; Sargiotto, A; Tarella, C; Zallio, F, 2001) |
| "Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone." | 7.68 | Therapy with mitoxantrone, ifosfamide, vindesine, and prednisolone for malignant lymphoma with adjustable doses and timing of courses. ( Furukawa, Y; Hiyoshi, M; Im, T; Inoue, T; Kishida, T; Okuda, K; Park, K; Sasaki, A; Tatsumi, N; Yamane, T, 1991) |
| "Two phase II trials of mitoxantrone in refractory malignant lymphoma have been conducted." | 7.67 | Mitoxantrone in malignant lymphoma. ( Gams, RA; Posner, L; Steinberg, J, 1984) |
| "Two phase II trials of mitoxantrone (Novantrone; dihydroxyanthracenedione) in refractory malignant lymphoma have been conducted." | 7.67 | Mitoxantrone in malignant lymphoma. ( Bryan, S; Case, D; Dukart, G; Gams, RA; Jones, S; Stein, R; Weiss, A, 1985) |
| "A phase II clinical trial of mitoxantrone in refractory or relapsed malignant lymphomas was conducted by a cooperative study involving 17 institutions." | 7.67 | [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas]. ( Kawagoe, H; Kimura, I; Kitani, T; Masaoka, T; Ogawa, M; Ohnoshi, T; Ohta, K; Sampi, K; Shirakawa, S; Yamada, K, 1986) |
| "A phase II study of mitoxantrone (MIT) was performed in 13 cases of refractory malignant lymphoma, 1 of Hodgkin's disease and 12 of non-Hodgkin lymphoma." | 7.67 | [A phase II study of mitoxantrone in malignant lymphoma]. ( Ibuka, T; Imai, K; Sakai, Y; Sasaki, T, 1986) |
| "A consecutive series of 21 previously untreated patients with low-grade non-Hodgkin lymphomas were treated with mitoxantrone 5 mg/m2 daily for 3 days every 3 weeks." | 7.67 | High activity of mitoxantrone in previously untreated low-grade lymphomas. ( Hansen, MM; Hansen, SW; Hou-Jensen, K; Nissen, NI; Pedersen-Bjergaard, J, 1988) |
| "A phase II study of mitoxantrone in nonHodgkin's lymphoma was conducted by the Southwest Oncology Group between July 1981 and May 1982." | 7.67 | Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study. ( Balcerzak, SP; Coltman, CA; Coltman, TM; Morrison, FS; Von Hoff, DD, 1984) |
| "A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma." | 7.67 | Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial. ( Carden, J; Dahlberg, S; Dana, B; Jones, SE; Kjeldsberg, CR; Mundis, R; Schnitzer, B; Tranum, B, 1989) |
| "The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule." | 7.66 | Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. ( Balcerzak, SP; Coltman, CA; McDaniel, TM; Morrison, FS; Von Hoff, DD, 1983) |
| "Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods." | 5.72 | Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. ( Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I, 2022) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 5.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Mitoxantrone is an anthracenedione with structural similarities to adriamycin but without the amino-sugar moiety on the parent molecule." | 5.27 | [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma]. ( Hiraki, S; Kimura, I; Miyamoto, H; Murashima, M; Ohnoshi, T; Toyata, K; Ueno, K; Ueoka, H; Yamane, T, 1985) |
| "Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol." | 5.22 | Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. ( Lee, JJ; Liao, AT; Wang, SL, 2016) |
| " In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)." | 5.11 | Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005) |
| "This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS)." | 5.10 | CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. ( Anderson, H; Björkholm, M; Cavallin-Stahl, E; Hagberg, H; Holte, H; Kvaløy, S; Myhre, J; Osby, E; Pertovaara, H; Teerenhovi, L, 2003) |
| "Fifty-one patients with recurrent or refractory indolent lymphoma were treated with a regimen of fludarabine 25 mg/m2/d intravenously (IV) on days 1 to 3, mitoxantrone 10 mg/m2 IV on day 1, and dexamethasone 20 mg/d IV or orally on days 1 to 5." | 5.08 | Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. ( Cabanillas, F; Hagemeister, FB; Keating, M; McLaughlin, P; Pate, O; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1996) |
| "Thirty cases (breast cancer-20 cases, malignant lymphoma-4 cases, different malignancies-6 cases) of histologically/cytologically verified malignant pleural effusion (MPE) in 29 patients were treated with intrapleurally instilled mitoxantrone (30 mg)." | 5.08 | Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study. ( Aasebø, U; Norum, J; Sager, G; Slørdal, L, 1997) |
| "We have previously reported that combination chemotherapy based on the drugs cytarabine/platinum is effective in recurring lymphomas." | 5.08 | A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. ( Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W, 1995) |
| "We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs." | 5.07 | [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993) |
| "We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation." | 5.07 | Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ( Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993) |
| "Mitoxantrone was administered to 74 dogs with lymphoma at a dosage of 5." | 5.07 | Evaluation of mitoxantrone for the treatment of lymphoma in dogs. ( Cotter, SM; Dennis, RA; Getzy, DM; L'Heureux, DA; Moore, AS; Ogilvie, GK; Rand, WS; Ruslander, D, 1994) |
| "Oral VP-16 combined with ifosfamide/mesna and mitoxantrone at the doses and schedules indicated has little activity against relapsed and/or refractory lymphomas." | 5.07 | A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. ( Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1994) |
| "As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease." | 5.07 | Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. ( Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ, 1991) |
| "We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)." | 5.07 | Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994) |
| " A phase II study was performed at the MTD of paclitaxel in patients with doxorubicin/mitoxantrone-refractory metastatic breast cancer." | 5.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "Twenty-seven patients with failed malignant lymphomas (19 with intermediate grade, 4 with low-grade, 3 with high-grade lymphomas, and 1 with Hodgkin's disease) who had failed a median of 3 prior multidrug regimens, all previously exposed to anthracyclines (median prior doxorubicin 360 mg/m2), were treated with a combination of mitoxantrone (M), vincristine (V), and dexamethasone (D) every 4 weeks." | 5.06 | Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphoma. ( Crown, JC; Holland, JF; Paciucci, PA, 1989) |
| "In order to compare the efficacy and toxicity of mitoxantrone and adriamycin in non-Hodgkin's lymphoma, a randomized trial has been conducted by a cooperative study group since June 1984." | 5.06 | [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. ( Kimura, I; Masaoka, T; Namba, K; Ohnoshi, T; Sampi, K, 1986) |
| "A phase II clinical trial of an anthraquinone, mitoxantrone was performed in a total of 31 patients with various advanced solid tumors and 2 patients with malignant lymphomas refractory to extensive prior chemotherapies." | 5.05 | [Phase II study of mitoxantrone]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Okada, Y; Tada, A; Usui, N, 1984) |
| "New clinical strategies and innovative approaches to the use of mitoxantrone include high-dose treatment, new combinations such as 5-fluorouracil with leucovorin (NFL), and neoadjuvant therapy for metastatic and primary breast cancer." | 4.79 | Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction. ( Powles, TJ, 1997) |
| "Mitoxantrone, a cytotoxic anthracenedione derivative, has given clinical evidence of beneficial activity in breast cancer, lymphoma and leukaemia." | 4.78 | Pharmacokinetics and metabolism of mitoxantrone. A review. ( Blanz, J; Ehninger, G; Proksch, B; Schuler, U; Zeller, KP, 1990) |
| "In breast cancer, mitoxantrone's response rate as a single agent is 25-30%, while combination regimens produce response rates of 60% or more." | 3.76 | Mitoxantrone: a novel anthracycline derivative. ( Eble, M; Koeller, J, 1988) |
| " The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma." | 3.73 | Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. ( Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A, 2005) |
| "From December 1995 to April 2003, 14 lymphoma and 29 acute leukemia patients were treated with high-dose cytarabine (2 g/m2 every 12 h, days 1 and 2) and mitoxantrone (10 mg/m2, days 2 and 3), followed by 300 microgram recombinant human granulocyte colony-stimulating factor per day (rhG-CSF 300 microg/d) i." | 3.72 | [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies]. ( Chang, WR; Fu, ZZ; Jin, ZM; Miao, M; Qiu, HY; Shen, YM; Sun, AN; Tang, XW; Wu, DP, 2004) |
| "Hematological and extrahematological toxicity of high-dose (hd) mitoxantrone (MITO) and melphalan (L-PAM) as conditioning regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at disease onset)." | 3.71 | High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. ( Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Gianni, AM; Ladetto, M; Pileri, A; Podio, V; Rossi, G; Sargiotto, A; Tarella, C; Zallio, F, 2001) |
| "Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)." | 3.68 | [Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| "Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone." | 3.68 | Therapy with mitoxantrone, ifosfamide, vindesine, and prednisolone for malignant lymphoma with adjustable doses and timing of courses. ( Furukawa, Y; Hiyoshi, M; Im, T; Inoue, T; Kishida, T; Okuda, K; Park, K; Sasaki, A; Tatsumi, N; Yamane, T, 1991) |
| "A phase II study of mitoxantrone (MIT) was performed in 13 cases of refractory malignant lymphoma, 1 of Hodgkin's disease and 12 of non-Hodgkin lymphoma." | 3.67 | [A phase II study of mitoxantrone in malignant lymphoma]. ( Ibuka, T; Imai, K; Sakai, Y; Sasaki, T, 1986) |
| "A consecutive series of 21 previously untreated patients with low-grade non-Hodgkin lymphomas were treated with mitoxantrone 5 mg/m2 daily for 3 days every 3 weeks." | 3.67 | High activity of mitoxantrone in previously untreated low-grade lymphomas. ( Hansen, MM; Hansen, SW; Hou-Jensen, K; Nissen, NI; Pedersen-Bjergaard, J, 1988) |
| "A phase II study of mitoxantrone in nonHodgkin's lymphoma was conducted by the Southwest Oncology Group between July 1981 and May 1982." | 3.67 | Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study. ( Balcerzak, SP; Coltman, CA; Coltman, TM; Morrison, FS; Von Hoff, DD, 1984) |
| "A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma." | 3.67 | Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial. ( Carden, J; Dahlberg, S; Dana, B; Jones, SE; Kjeldsberg, CR; Mundis, R; Schnitzer, B; Tranum, B, 1989) |
| "Two phase II trials of mitoxantrone in refractory malignant lymphoma have been conducted." | 3.67 | Mitoxantrone in malignant lymphoma. ( Gams, RA; Posner, L; Steinberg, J, 1984) |
| "A phase II clinical trial of mitoxantrone in refractory or relapsed malignant lymphomas was conducted by a cooperative study involving 17 institutions." | 3.67 | [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas]. ( Kawagoe, H; Kimura, I; Kitani, T; Masaoka, T; Ogawa, M; Ohnoshi, T; Ohta, K; Sampi, K; Shirakawa, S; Yamada, K, 1986) |
| " Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone." | 3.67 | [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. ( Hattori, M; Honda, T; Sampi, K, 1984) |
| "The pharmacokinetics of mitoxantrone, an anthraquinone antitumor agent, were cooperatively investigated at 5 institutions including 4 patients with breast cancer and 3 patients with malignant lymphoma." | 3.67 | [Pharmacokinetic study of mitoxantrone]. ( Ogawa, M; Oguro, M; Sakai, K; Sampi, K; Tsukui, T, 1986) |
| "Two phase II trials of mitoxantrone (Novantrone; dihydroxyanthracenedione) in refractory malignant lymphoma have been conducted." | 3.67 | Mitoxantrone in malignant lymphoma. ( Bryan, S; Case, D; Dukart, G; Gams, RA; Jones, S; Stein, R; Weiss, A, 1985) |
| "The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule." | 3.66 | Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. ( Balcerzak, SP; Coltman, CA; McDaniel, TM; Morrison, FS; Von Hoff, DD, 1983) |
| "Mitoxantrone was given at either doses of 3, 5, or 6 mg/m2 daily X 5 in 8 patients with acute leukemia, while 10 patients with NHL were given intravenously at a dose of 10, 12, or 14 mg/m2 every 3 to 4 weeks." | 2.65 | [Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies]. ( Hattori, M; Hayashi, Y; Honda, T; Sampi, K, 1983) |
| "The usual doses used in solid tumors and in lymphomas are mitoxantrone 12-14 mg/m2 iv q3-4wk and in leukemias is mitoxantrone 12 mg/m2/d X 5 d iv for initial induction." | 2.37 | Mitoxantrone. ( Poirier, TI, 1986) |
| "B-cell lymphoma is one of the most common types of lymphoma, and chemotherapy is still the current first-line treatment." | 1.72 | Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma. ( Guo, K; Li, S; Tong, R; Yin, X; Zhang, Q, 2022) |
| "Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods." | 1.72 | Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. ( Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I, 2022) |
| "Rather for several types of cancer a significantly reduced risk was observed, except for breast cancer in women treated with IS." | 1.35 | Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008) |
| " We analyzed the induction of apoptosis by 2-CdA alone (n=5) and in combination with other drugs in peripheral lymphocytes from 25 patients with leukemic low-grade lymphomas and from 25 healthy volunteers." | 1.31 | Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. ( Boehrer, S; Chow, KU; Hoelzer, D; Jantschke, P; Martin, H; Mitrou, PS; Napieralski, S; Pourebrahim, F; Ries, J; Rummel, MJ; Stein, J; Weidmann, E, 2000) |
| " Mitoxantrone plasma samples were obtained prior to dosing and at 0, 0." | 1.28 | Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis. ( Battaglia, AC; Boros, L; Cacek, T; Pine, RB, 1992) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 1.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Mitoxantrone is an anthracenedione with structural similarities to adriamycin but without the amino-sugar moiety on the parent molecule." | 1.27 | [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma]. ( Hiraki, S; Kimura, I; Miyamoto, H; Murashima, M; Ohnoshi, T; Toyata, K; Ueno, K; Ueoka, H; Yamane, T, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (42.17) | 18.7374 |
| 1990's | 27 (32.53) | 18.2507 |
| 2000's | 16 (19.28) | 29.6817 |
| 2010's | 3 (3.61) | 24.3611 |
| 2020's | 2 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Q | 1 |
| Li, S | 1 |
| Guo, K | 1 |
| Yin, X | 1 |
| Tong, R | 1 |
| Gunes, AK | 1 |
| Serin, I | 1 |
| Demir, I | 1 |
| Sarifakiogullari, S | 1 |
| Durusoy, SS | 1 |
| Akkurt, DM | 1 |
| Ince, I | 1 |
| Ozkan, G | 1 |
| Cinli, TA | 1 |
| Pehlivan, M | 1 |
| Okay, M | 1 |
| Büyükaşık, Y | 1 |
| Demiroğlu, H | 1 |
| Malkan, ÜY | 1 |
| Çiftçiler, R | 1 |
| Aladağ, E | 1 |
| Aksu, S | 1 |
| Haznedaroğlu, İC | 1 |
| Sayınalp, N | 1 |
| Özcebe, Oİ | 1 |
| Göker, H | 1 |
| Wang, SL | 1 |
| Lee, JJ | 1 |
| Liao, AT | 1 |
| Daters, AT | 1 |
| Mauldin, GE | 1 |
| Mauldin, GN | 1 |
| Brodsky, EM | 1 |
| Post, GS | 1 |
| Emmanouilides, C | 2 |
| Lill, M | 1 |
| Telatar, M | 1 |
| Rosenfelt, F | 1 |
| Grody, W | 1 |
| Territo, M | 2 |
| Rosen, P | 2 |
| Osby, E | 1 |
| Hagberg, H | 1 |
| Kvaløy, S | 1 |
| Teerenhovi, L | 1 |
| Anderson, H | 1 |
| Cavallin-Stahl, E | 1 |
| Holte, H | 1 |
| Myhre, J | 1 |
| Pertovaara, H | 1 |
| Björkholm, M | 1 |
| Chow, KU | 2 |
| Nowak, D | 1 |
| Boehrer, S | 2 |
| Ruthardt, M | 1 |
| Knau, A | 1 |
| Hoelzer, D | 2 |
| Mitrou, PS | 2 |
| Weidmann, E | 2 |
| Menco, H | 1 |
| Patel, R | 1 |
| Qiu, HY | 1 |
| Wu, DP | 1 |
| Sun, AN | 1 |
| Chang, WR | 1 |
| Jin, ZM | 1 |
| Miao, M | 1 |
| Tang, XW | 1 |
| Shen, YM | 1 |
| Fu, ZZ | 1 |
| McLaughlin, P | 5 |
| Estey, E | 1 |
| Glassman, A | 1 |
| Romaguera, J | 2 |
| Samaniego, F | 1 |
| Ayala, A | 2 |
| Hayes, K | 1 |
| Maddox, AM | 1 |
| Preti, HA | 1 |
| Hagemeister, FB | 5 |
| Tsimberidou, AM | 1 |
| Younes, A | 3 |
| Rodriguez, MA | 4 |
| Feng, L | 1 |
| Smith, TL | 1 |
| Cabanillas, F | 5 |
| Papadopoulos, KP | 1 |
| Noguera-Irizarry, W | 1 |
| Wiebe, L | 1 |
| Hesdorffer, CS | 1 |
| Garvin, J | 1 |
| Nichols, GL | 1 |
| Vahdat, LH | 1 |
| Lo, KM | 1 |
| Skerrett, D | 1 |
| Bernstein, D | 1 |
| Sharpe, E | 1 |
| Savage, DG | 1 |
| Kogoshi, H | 1 |
| Tohda, S | 1 |
| Fu, L | 1 |
| Koyama, T | 1 |
| Nara, N | 1 |
| Oyan, B | 1 |
| Koc, Y | 1 |
| Ozdemir, E | 1 |
| Kars, A | 1 |
| Turker, A | 1 |
| Tekuzman, G | 1 |
| Kansu, E | 1 |
| Lebrun, C | 1 |
| Debouverie, M | 1 |
| Vermersch, P | 1 |
| Clavelou, P | 1 |
| Rumbach, L | 1 |
| de Seze, J | 1 |
| Wiertlevski, S | 1 |
| Defer, G | 1 |
| Gout, O | 1 |
| Berthier, F | 1 |
| Danzon, A | 1 |
| Sampi, K | 5 |
| Honda, T | 2 |
| Hattori, M | 2 |
| Hayashi, Y | 1 |
| Tada, A | 1 |
| Ogawa, M | 3 |
| Usui, N | 1 |
| Inagaki, J | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Ikeda, K | 1 |
| Adachi, K | 1 |
| Nakada, H | 1 |
| Okada, Y | 1 |
| Gams, RA | 4 |
| Steinberg, J | 2 |
| Posner, L | 1 |
| Coltman, CA | 3 |
| Coltman, TM | 1 |
| Balcerzak, SP | 3 |
| Morrison, FS | 3 |
| Von Hoff, DD | 3 |
| Nathanson, L | 1 |
| De Jager, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Keiling, R | 1 |
| Fargeot, P | 1 |
| Bastit, P | 1 |
| van Glabbeke, M | 1 |
| Renard, J | 1 |
| Earl, H | 1 |
| Rubens, R | 1 |
| Ueoka, H | 2 |
| Ueno, K | 2 |
| Yamane, T | 4 |
| Toyoda, K | 1 |
| Endo, H | 1 |
| Nishihara, R | 1 |
| Takahashi, I | 1 |
| Ohnoshi, T | 4 |
| Kitajima, K | 1 |
| Kimura, I | 4 |
| Keller, JW | 1 |
| Golomb, HM | 1 |
| Dukart, G | 2 |
| McDaniel, TM | 2 |
| Fuchsberger, P | 1 |
| Lakota, J | 1 |
| Lichtman, SM | 1 |
| Romaguera, JE | 3 |
| Swan, F | 3 |
| Moore, DF | 1 |
| Sarris, AH | 2 |
| Hill, D | 1 |
| Wilson, WH | 1 |
| Berg, SL | 1 |
| Bryant, G | 1 |
| Wittes, RE | 1 |
| Bates, S | 1 |
| Fojo, A | 1 |
| Steinberg, SM | 1 |
| Goldspiel, BR | 1 |
| Herdt, J | 1 |
| O'Shaughnessy, J | 1 |
| Bezwoda, WR | 1 |
| Rastogi, RB | 1 |
| Moore, AS | 3 |
| Ogilvie, GK | 3 |
| Ruslander, D | 1 |
| Rand, WS | 1 |
| Cotter, SM | 1 |
| Getzy, DM | 1 |
| L'Heureux, DA | 1 |
| Dennis, RA | 1 |
| Attal, M | 2 |
| Canal, P | 2 |
| Schlaifer, D | 2 |
| Chatelut, E | 2 |
| Dezeuze, A | 1 |
| Huguet, F | 2 |
| Payen, C | 1 |
| Pris, J | 1 |
| Laurent, G | 2 |
| Matsuishi, H | 1 |
| Harada, M | 1 |
| Gondo, H | 1 |
| Otsuka, T | 1 |
| Teshima, T | 1 |
| Yamano, Y | 1 |
| Omori, F | 1 |
| Shibuya, T | 1 |
| Yamazaki, K | 1 |
| Taniguchi, S | 1 |
| Guichard, S | 1 |
| Muller, C | 1 |
| Houin, G | 1 |
| Bugat, R | 1 |
| Cabanillas, FC | 1 |
| Velasquez, W | 1 |
| Pate, O | 1 |
| Keating, M | 1 |
| Aasebø, U | 1 |
| Norum, J | 1 |
| Sager, G | 1 |
| Slørdal, L | 1 |
| Powles, TJ | 1 |
| Bairey, O | 1 |
| Gabbay, U | 1 |
| Blickstein, D | 1 |
| Stark, P | 1 |
| Prokocimer, M | 1 |
| Epstein, O | 1 |
| Shaklai, M | 1 |
| Lahav, J | 1 |
| Gómez, H | 1 |
| Colomer, R | 1 |
| Sanna, P | 1 |
| Van den Bosch, S | 1 |
| Cavalli, F | 1 |
| Ghielmini, M | 1 |
| Porter, P | 1 |
| Cornaby, AJ | 1 |
| al-Hilali, M | 1 |
| Chakrabarti, AM | 1 |
| Robak, T | 1 |
| Góra-Tybor, J | 1 |
| Chojnowski, K | 1 |
| Rummel, MJ | 1 |
| Ries, J | 1 |
| Jantschke, P | 1 |
| Pourebrahim, F | 1 |
| Napieralski, S | 1 |
| Stein, J | 1 |
| Martin, H | 1 |
| Tarella, C | 1 |
| Zallio, F | 1 |
| Caracciolo, D | 1 |
| Cuttica, A | 1 |
| Corradini, P | 1 |
| Gavarotti, P | 1 |
| Ladetto, M | 1 |
| Podio, V | 1 |
| Sargiotto, A | 1 |
| Rossi, G | 1 |
| Gianni, AM | 1 |
| Pileri, A | 1 |
| Mayer, J | 1 |
| Vásová, I | 1 |
| Korístek, Z | 1 |
| Navrátil, M | 1 |
| Klabusay, M | 1 |
| Doubek, M | 1 |
| Vorlícek, J | 1 |
| Cernilová, I | 1 |
| Vodvárka, P | 1 |
| Petráková, K | 1 |
| Hosomi, Y | 1 |
| Shibuya, M | 1 |
| Boros, L | 1 |
| Cacek, T | 1 |
| Pine, RB | 1 |
| Battaglia, AC | 1 |
| Arai, N | 1 |
| Hara, A | 1 |
| Umeda, M | 1 |
| Shirai, T | 1 |
| Crown, JP | 1 |
| Gulati, S | 1 |
| Straus, DJ | 1 |
| Kolitz, J | 1 |
| Heelan, R | 1 |
| O'Brien, J | 1 |
| Lee, BJ | 1 |
| Portlock, C | 1 |
| Bertino, J | 1 |
| Inoue, T | 1 |
| Furukawa, Y | 1 |
| Hiyoshi, M | 2 |
| Sasaki, A | 2 |
| Kishida, T | 2 |
| Park, K | 1 |
| Im, T | 1 |
| Tatsumi, N | 1 |
| Okuda, K | 1 |
| Obradovich, JE | 2 |
| Elmslie, RE | 2 |
| Vail, DM | 2 |
| Curtis, CR | 1 |
| Straw, RC | 2 |
| Dickinson, K | 2 |
| Cooper, MF | 2 |
| Withrow, SJ | 2 |
| Ehninger, G | 1 |
| Schuler, U | 1 |
| Proksch, B | 1 |
| Zeller, KP | 1 |
| Blanz, J | 1 |
| Ohtsu, T | 2 |
| Ishida, Y | 2 |
| Tobinai, K | 2 |
| Minato, K | 2 |
| Hamada, H | 2 |
| Ohkochi, E | 1 |
| Tsuruo, T | 2 |
| Shimoyama, M | 2 |
| Green, AR | 1 |
| Campbell, IA | 1 |
| Poynton, C | 1 |
| Bentley, DP | 1 |
| Sugimoto, Y | 1 |
| Paciucci, PA | 1 |
| Crown, JC | 1 |
| Holland, JF | 1 |
| Coiffier, B | 1 |
| Dana, B | 1 |
| Dahlberg, S | 1 |
| Schnitzer, B | 1 |
| Kjeldsberg, CR | 1 |
| Jones, SE | 1 |
| Carden, J | 1 |
| Mundis, R | 1 |
| Tranum, B | 1 |
| Janmohammed, R | 1 |
| Milligan, DW | 1 |
| Koeller, J | 1 |
| Eble, M | 1 |
| Cotter, FE | 1 |
| Tsukagoshi, S | 1 |
| Hansen, SW | 1 |
| Nissen, NI | 1 |
| Hansen, MM | 1 |
| Hou-Jensen, K | 1 |
| Pedersen-Bjergaard, J | 1 |
| Okuma, K | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Ho, AD | 1 |
| Seither, E | 1 |
| Ma, DD | 1 |
| Prentice, HG | 1 |
| Poirier, TI | 1 |
| Masaoka, T | 2 |
| Namba, K | 1 |
| Sannomiya, Y | 1 |
| Sagawa, H | 1 |
| Yokomatsu, Y | 1 |
| Kojima, K | 1 |
| Yoshikawa, T | 1 |
| Tatsumi, J | 1 |
| Esseesse, I | 1 |
| Bartolucci, AA | 1 |
| Silberman, H | 1 |
| Velez-Garcia, E | 1 |
| Cohen, HJ | 1 |
| Omura, GA | 1 |
| Ibuka, T | 1 |
| Sasaki, T | 1 |
| Imai, K | 1 |
| Sakai, Y | 1 |
| Yamada, K | 1 |
| Ohta, K | 1 |
| Kitani, T | 1 |
| Kawagoe, H | 1 |
| Shirakawa, S | 1 |
| Tsukui, T | 1 |
| Oguro, M | 1 |
| Sakai, K | 1 |
| Manandhar, M | 1 |
| Cheng, M | 1 |
| Iatropoulos, MJ | 1 |
| Noble, JF | 1 |
| Bryan, S | 1 |
| Weiss, A | 1 |
| Case, D | 1 |
| Jones, S | 1 |
| Stein, R | 1 |
| Hiraki, S | 1 |
| Toyata, K | 1 |
| Miyamoto, H | 1 |
| Murashima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma[NCT02431403] | Phase 1/Phase 2 | 94 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma.[NCT00169208] | Phase 2 | 50 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for mitoxantrone and Germinoblastoma
| Article | Year |
|---|---|
Lymphoma in the older patient.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; | 1995 |
Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Leukemia; Lymphoma; Mitoxantrone | 1997 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 1998 |
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2001 |
Pharmacokinetics and metabolism of mitoxantrone. A review.
Topics: Animals; Breast Neoplasms; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Leu | 1990 |
Mitoxantrone: a novel anthracycline derivative.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi | 1988 |
Therapeutic milestones. Novantrone (mitozantrone).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leukemia; Lymphoma | 1988 |
Mitoxantrone.
Topics: Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Humans; Kinetics; Lymphoma; Mitoxantr | 1986 |
26 trials available for mitoxantrone and Germinoblastoma
| Article | Year |
|---|---|
Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2016 |
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Dog Disease | 2010 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2002 |
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxor | 2003 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2005 |
Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem | 2005 |
High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lympho | 2006 |
[Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child, Preschool; Clinical Trials as | 1983 |
[Phase II study of mitoxantrone].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Human | 1984 |
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1994 |
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Topics: Adult; Aged; Agranulocytosis; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Resi | 1994 |
A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Mit | 1994 |
Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
Topics: Animals; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone; Remission Induction | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 1994 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyta | 1993 |
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Topics: Adult; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; M | 1993 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; | 1995 |
Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma; Male; | 1996 |
Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, A | 1997 |
Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Graft Survival | 2001 |
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hodgk | 1991 |
Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood; Clinical Trials as Topic; Dexame | 1989 |
[Evaluation of mitoxantrone in 1989].
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Leukemia; Lymphoma; Mal | 1989 |
Mitoxantrone: a novel anthracycline derivative.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi | 1988 |
[Introduction of a new anticancer drug, novantrone].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; | 1987 |
[A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1986 |
50 other studies available for mitoxantrone and Germinoblastoma
| Article | Year |
|---|---|
Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma.
Topics: Animals; Apoptosis; Immunity; Lymphoma; Lymphoma, B-Cell; Mice; Mitoxantrone | 2022 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 2022 |
Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation\
in relapsed/refractory lymphoma
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Hum | 2019 |
Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apo | 2003 |
Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineopla | 2003 |
[Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte C | 2004 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; De | 2005 |
Effect of notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells.
Topics: Antineoplastic Agents; Calcium-Binding Proteins; Caspase 3; Caspases; Cell Line, Tumor; Cell Prolife | 2005 |
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Topics: Adult; Azathioprine; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Digestive | 2008 |
[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
Mitoxantrone in malignant lymphoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Hodgkin Disease; Humans; Lymphoma; Mitoxantr | 1984 |
Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukocyte Count; Lymphoma; Mitoxantr | 1984 |
Mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Evaluation; Hear | 1984 |
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom | 1984 |
[Phase II study of mitoxantrone for hematologic malignancies].
Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Hu | 1983 |
Mitoxantrone in malignant lymphomas.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Hodgkin Disease; Humans; Intercalating Agent | 1983 |
Mitoxantrone hydrochloride in lymphoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Heart; Hodgkin Disease; Humans; Intercalatin | 1983 |
Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
Topics: Anthraquinones; Drug Evaluation; Hodgkin Disease; Humans; Infusions, Parenteral; Lymphoma; Mitoxantr | 1983 |
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclo | 1995 |
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide | 1994 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherap | 1997 |
High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; | 1998 |
Primary lymphoma of the bladder treated successfully with mitozantrone gel.
Topics: Administration, Intravesical; Adult; Antineoplastic Agents; Gels; Humans; Lymphoma; Male; Mitoxantro | 1999 |
Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; Female; Huma | 2000 |
Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Apoptosis; Deoxyadenosines; Dose-Response Relationship, Dr | 2000 |
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; | 2001 |
Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis.
Topics: Aged; Female; Humans; Lymphoma; Mitoxantrone; Renal Dialysis; Renal Insufficiency; Time Factors; Tis | 1992 |
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; F | 1991 |
Therapy with mitoxantrone, ifosfamide, vindesine, and prednisolone for malignant lymphoma with adjustable doses and timing of courses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Ifosfamide; Le | 1991 |
Clinical evaluation of mitoxantrone in lymphoma therapy. June 6, 1990, Lugano,Switzerland. Proceedings.
Topics: Humans; Lymphoma; Mitoxantrone | 1990 |
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Topics: Animals; Anorexia; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone; | 1991 |
Efficacy of mitoxantrone against various neoplasms in dogs.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Lymphoma; Mitoxantrone; Neoplasms; Prospective Studies; Remi | 1991 |
A novel multidrug resistance in cultured leukemia and lymphoma cells detected by a monoclonal antibody to 85-kDa protein, MRK20.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Drug Resistance; Humans; Immunoglobulin Fab Fra | 1989 |
Acute myeloid leukaemia presenting with pleural effusions.
Topics: Antigens, Differentiation; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cytar | 1989 |
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Dauno | 1989 |
Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1989 |
Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Heart Failure; Humans; Leukemia, | 1989 |
High activity of mitoxantrone in previously untreated low-grade lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Drug Administration Schedule; Drug Evaluation; Female | 1988 |
[Cardiotoxicity of mitoxantrone].
Topics: Adolescent; Adult; Aged; Blast Crisis; Child; Doxorubicin; Electrocardiography; Female; Heart; Heart | 1986 |
Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells.
Topics: Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Humans; Leukemia; Leukemia, Myeloid, Acute; Lym | 1987 |
[MCOP therapy of malignant lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fe | 1987 |
Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Topics: Adult; Aged; Anthraquinones; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lym | 1986 |
[A phase II study of mitoxantrone in malignant lymphoma].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; E | 1986 |
[A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Topics: Adolescent; Adult; Aged; Anorexia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Child; Child, | 1986 |
Mitozantrone.
Topics: Breast Neoplasms; Humans; Leukemia; Liver Neoplasms; Lymphoma; Mitoxantrone; Neoplasms | 1986 |
[Pharmacokinetic study of mitoxantrone].
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; | 1986 |
Genetic toxicology profile of the new antineoplastic drug mitoxantrone in the mammalian test systems.
Topics: Animals; Biotransformation; Cell Transformation, Neoplastic; DNA; DNA Repair; Genes, Dominant; Genes | 1986 |
Mitoxantrone in malignant lymphoma.
Topics: Alopecia; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukocyte Count; Lymphoma; | 1985 |
[Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
Topics: Adult; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1985 |